Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022113 · ClinicalTrials.gov registry record · Phase 1
EMD 121974 in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00022113: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00022113 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00022113, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of EMD 121974 in treating patients who have advanced solid tumors. EMD 121974 may slow the growth of solid tumors by stopping blood flow to the tumor
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG cilengitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2001-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022113
The ClinicalTrials.gov registry entry for NCT00022113 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00022113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00022113 about?
NCT00022113 is a clinical study titled "EMD 121974 in Treating Patients With Advanced Solid Tumors". Phase I trial to study the effectiveness of EMD 121974 in treating patients who have advanced solid tumors. EMD 121974 may slow the growth of solid tumors by stopping blood flow to the tumor
What is the current status of trial NCT00022113?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2001-05.
What interventions are being tested in trial NCT00022113?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), cilengitide (DRUG).
Who is sponsoring clinical trial NCT00022113?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.